Skip to main content
. Author manuscript; available in PMC: 2019 Nov 18.
Published in final edited form as: JAMA Pediatr. 2016 May 1;170(5):459–465. doi: 10.1001/jamapediatrics.2016.0047

Table 1.

Transmission Model Estimates of Pertussis Incidence, Complications, and Vaccine-Related Adverse Effects 10 Years Into the Second Epoch

Characteristic Age Group, y Total
<1 1–6 7–18 >18
B pertussis incidence, % decrease (95% CI)
 Infection 96 (92–98) 95 (91–98) 95 (91–98) 95 (91–98) 95 (91–98)
 Rate of hospitalization 96 (91–97) 95 (93–96) 95 (90–98) 96 (92–99) 96 (95–99)
 Infant death rate 96 (92–98) NA NA NA NA
B pertussis complications, % decrease (95% CI)
 Rate of pneumonia 95 (92–99) 95 (92–99) 95 (92–98) 96 (93–99) 96 (92–99)
 Rate of seizures 95 (92–99) 95 (91–99) NA NA 96 (92–99)
 Rate of encephalopathy 96 (92–99) NA NA NA NA
Vaccine-associated adverse effects, % increase (95% CI)
 Persistent, inconsolable crying 175 (161–188) 686 (539–833) NA NA 632 (370–894)
 Rate of fever 811 (794–851) 3150 (2453–3865) NA NA 2917 (1642–4180)
 Rate of seizures 63 (53–74) 261 (212–311) NA NA 240 (152–333)
 Rate of encephalopathy 5.78 × 10−4 (5.59–5.87 × 10−4) NA NA NA NA

Abbreviations: aP, acelullar pertussis; B pertussis, Bordetella pertussis; NA, not applicable.